The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
The clinical utility of bone marker measurements in osteoporosis
Open accessAbstract
Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, resulting in increased fragility and susceptibility to fracture. Osteoporotic fractures are a significant cause of morbidity and mortality. Direct medical costs from such fractures in the UK are currently estimated at over two billion pounds per year, resulting in a substantial healthcare burden that is expected to rise exponentially due to increasing life expectancy. Currently bone mineral density is the WHO standard for diagnosis of osteoporosis, but poor sensitivity means that potential fractures will be missed if it is used alone. During the past decade considerable progress has been made in the identification and characterisation of specific biomarkers to aid the management of metabolic bone disease. Technological developments have greatly enhanced assay performance producing reliable, rapid, non-invasive cost effective assays with improved sensitivity and specificity. We now have a greater understanding of the need to regulate pre-analytical sample collection to minimise the effects of biological variation. However, bone turnover markers (BTMs) still have limited clinical utility. It is not routinely recommended to use BTMs to select those at risk of fractures, but baseline measurements of resorption markers are useful before commencement of anti-resorptive treatment and can be checked 3-6 months later to monitor response and adherence to treatment. Similarly, formation markers can be used to monitor bone forming agents. BTMs may also be useful when monitoring patients during treatment holidays and aid in the decision as to when therapy should be recommenced. Recent recommendations by the Bone Marker Standards Working Group propose to standardise research and include a specific marker of bone resorption (CTX) and bone formation (P1NP) in all future studies. It is hoped that improved research in turn will lead to optimised markers for the clinical management of osteoporosis and other bone diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Mechanism of blockade of the Wnt signalling pathway by osteocytes. Osteocytes detect changes in bone morphology through their sensitivity to mechanical forces, thereby regulating bone turnover through direct physical contact with osteoblasts. Osteocytes produce OPN, DMP, MEPE, SCL and DKK-1. The β-catenin-dependent canonical Wnt signalling pathway controls gene expression by stabilizing β-catenin in regulating a diverse array of biological processes. It is initiated by binding of appropriate Wnt ligands to the frizzled (Fz) and low-density lipoprotein receptor-related proteins 5 and 6 (LRP-5/6) and can be antagonized by secreted proteins from SCL and the DKK family, that bind with high affinity to LRP-5 or LRP-6, thereby directly prevent Wnt binding. Wnt proteins act on osteoblast precursor cells through this pathway and promote their differentiation into mature osteoblasts. In addition, they can suppress bone resorption by up-regulating OPG and down-regulating RANKL expression in mature osteoblasts, leading to a net increase in bone mass [6]. Additionally research has targeted the complex regulation of osteocyte action by expression of PTH/PTHrP receptor’s (PPR’s). Osteocyte activation of PPR leads to down-regulation of Sost and increased Wnt signalling stimulating bone formation, accompanied by up-regulation of RANKL expression and osteoclast number increasing resorption. In contrast the main effect of PPR deletion on osteocytes is reduced osteoclast and osteoblast numbers and decreased bone remodelling [7].](https://figures.cochat.ai/paper-figures/0c8cf31d8e9949f19698bcd8f377dfd8/the-clinical-utility-of-bone-marker-measurements-in-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“OPG, a soluble receptor also produced by osteoblasts that acts as a decoy receptor and neutralizes RANKL, prevents RANKL from interacting with RANK and consequently inhibits osteoclast proliferation, activity, and survival [73, 74].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Examples of bone formation markers include alkaline phosphatase (ALP) and osteocalcin (OC), which quantify osteoblastic activity.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, ALP has low sensitivity and specificity in metabolic bone disorders since it is secreted by various tissues, including the liver, bone, and placenta [54,55].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [54]
Experimental — accuracy not yet measuredIn the citing paper
“RANKL, released by osteoblasts, binds its receptor located on the surface of osteoclast precursor cells, promoting their differentiation and triggering bone resorption, whereas OPG, also released by osteoblasts, interacts with RANK, preventing the binding with its ligand and inhibiting the activity and proliferation of osteoclasts [47].”
From Skeletal System Biology and Smoke Damage: From Basic Science to Medical Clinic (2021) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schuit, S. C. E., van der Klift, M., Weel, A. E. A. M., de Laet, C. E. D. H., Burger, H., Seeman, E., Hofman, A., Uitterlinden, A. G., van Leeuwen, J. P. T. M., & Pols, H. A. P. (2004) · Bone · doi:10.1016/j.bone.2003.10.001 · Cited by 1,651 · cited 1×
“threshold [84].”
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis
Staa, T. P. V., Staa, T. P. V., Staa, T. P. V., Leufkens, H. G. M., & Cooper, C. (2002) · Osteoporosis International · doi:10.1007/s001980200108 · Cited by 1,294
A reference standard for the description of osteoporosis
Kanis, J. A., McCloskey, E. V., Johansson, H., Oden, A., Melton, L. J., & Khaltaev, N. (2008) · Bone · doi:10.1016/j.bone.2007.11.001 · Cited by 1,234 · cited 1×
“Currently the WHO recommends the use of BMD of the spine and proximal femur measured by DXA as the gold standard to diagnose osteoporosis and its severity [12].”
Methodfor the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
The Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 722
Garnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709 · cited 4×
“associated with an increased fracture risk [28], but their use alone to predict fracture has yet to be established.”
BackgroundInfluentialBaim, S., Leonard, M. B., Bianchi, M.-L., Hans, D. B., Kalkwarf, H. J., Langman, C. B., & Rauch, F. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.002 · Cited by 707
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 628
Cited by
Talukdar, S., Zhou, Y., Li, D., Rossulek, M., Dong, J., Somayaji, V., Weng, Y., Clark, R., Lanba, A., Owen, B. M., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.001 · Cited by 496
“The effects of PF-05231023 on bone formation and resorption in humans have been examined using bone markers recommended by the Bone Marker Standards Working Group (Wheater et al., 2013).”
MethodCurrent Status of the Diagnosis and Management of Osteoporosis
Aibar-Almazán, A., Voltes-Martínez, A., Castellote-Caballero, Y., Afanador-Restrepo, D. F., Carcelén-Fraile, M. D. C., & López-Ruiz, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169465 · Cited by 412
“carboxy-terminal ends in processes of bone matrix formation or degradation [79].”
BackgroundCysteine Cathepsins and Their Extracellular Roles: Shaping the Microenvironment
Vidak, E., Javoršek, U., Vizovišek, M., & Turk, B. (2019) · Cells · doi:10.3390/cells8030264 · Cited by 398
Bone turnover markers: Emerging tool in the management of osteoporosis
Shetty, S., Kapoor, N., Bondu, J. D., Thomas, N., & Paul, T. V. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.192914 · Cited by 330
“[26] b one T uRnoveR m aRKeR a ssays Automated and manual immunoassay and multiplex microarrays are available for the analysis of BTMs for clinical and research purposes.”
MethodThe Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms
Al-Bashaireh, A. M., Haddad, L. G., Weaver, M., Chengguo, X., Kelly, D. L., & Yoon, S. (2018) · Journal of Osteoporosis · doi:10.1155/2018/1206235 · Cited by 209
Metadata
- Authors
- Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K., & van Laar, J. M.
- Affiliations
- James Cook University Hospital (GB)
- Newcastle University (GB)
- Corresponding author
- Wheater, Gillian
- Venue
- Journal of Translational Medicine
- Published
- 2013
- Volume
- 11
- Issue
- 1
- Pages
- 201
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC3765909
- OpenAlex
- W1967644150
- Cited by
- 322
- References
- 89
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 23 · 2023: 25 · 2022: 12 · 2021: 30 · 2020: 34 · 2019: 32 · 2018: 45 · 2017: 27 · 2016: 32 · 2015: 23 · 2014: 8 · 2013: 1
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- James Cook University
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, bone turnover markers, bone resorption markers, bone formation markers, osteocalcin, P1NP, CTX, osteoporotic fractures, bone mineral density, biological variation, treatment holidays, metabolic bone disease
- MeSH terms
- Bone and Bones, Diagnostic Tests, Routine, Humans, Osteoporosis, Biomarkers, Bone Remodeling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical utility of bone marker measurements in osteoporosis. https://app.cochat.ai/papers/10.1186/1479-5876-11-201
- The paper
- Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K., & van Laar, J. M. (2013). The clinical utility of bone marker measurements in osteoporosis. Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-11-201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.